J
Jean Luc Harousseau
Researcher at University of Nantes
Publications - 82
Citations - 16270
Jean Luc Harousseau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 46, co-authored 82 publications receiving 14925 citations. Previous affiliations of Jean Luc Harousseau include University of Pennsylvania & Hotel Dieu Hospital.
Papers
More filters
Journal ArticleDOI
Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation
Laurent Garderet,Simona Iacobelli,Philippe Moreau,Mamoun Dib,Denis Caillot,Dietger Niederwieser,Tamas Masszi,Jean Fontan,Mauricette Michallet,Alois Gratwohl,Giuseppe Milone,Chantal Doyen,Brigitte Pegourie,Roman Hájek,Philippe Casassus,Brigitte Kolb,Carine Chaleteix,Bernd Hertenstein,Francesco Onida,Heinz Ludwig,Marie Christiane Vekemans,Nicolas Ketterer,Anne Daguenel,Norbert Claude Gorin,Jean Luc Harousseau,Theo de Witte,Curly Morris,Gösta Gahrton +27 more
TL;DR: VTD resulted in significantly longer TTP and PFS in patients relapsing after ASCT with an acceptable toxicity, and was found to be more effective than either VTD or TD alone.
Journal ArticleDOI
Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
Jean-François Chatal,Jean Luc Harousseau,Frank Griesinger,Johannes Meller,C. Renner,Carl-Martin Kirsch,Ralph Naumann,Joachim Kropp,William A. Wegener,David M. Goldenberg +9 more
TL;DR: Dose escalation is continuing, with no serious AEs considered treatment-related, and therapy was well tolerated with no significa...
Journal ArticleDOI
Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.
Ruben Niesvizky,P. G. Richardson,Pieter Sonneveld,Michael W. Schuster,Morton Coleman,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean Luc Harousseau,Anthony Boral,KC Anderson +10 more
TL;DR: Increasing quality of response to btz is associated with greater clinical benefit assessed by extended TFI ,TTAT, and TTP, as defined by treatment-free interval and time-to-alternative-therapy, which support maximizing tumor mass reduction to CR/nCR with btz to achieve greater clinical Benefit.
Journal Article
High-dose etoposide and cisplatin in refractory or recurrent non-Hodgkin's lymphomas (NHL).
Philippe Colombat,P. Biron,C. Patte,Jean Luc Harousseau,F Demeocq,E Benz-Lemoine,D Frappaz,J. P. Lamagnere,Philip T +8 more
TL;DR: This combination is an effective salvage regime before autologous bone marrow transplantation for relapsed NHL, but cannot be recommended for progression on front-line therapy.
Journal ArticleDOI
Blockade of p110delta isoform activity of phosphoinositide 3-kinase inhibits blast cell proliferation in acute myeloblastic leukemia.
Didier Bouscary,Valérie Bardet,Pierre Sujobert,Pascale Cornillet-Lefebvre,Joel S. Hayflick,N. Prie,Frédérique Verdier,Bart Vanhaesebroeck,Odile Muller,F. Pesce,Norbert Ifrah,M. Hunault Berger,C. Bertho,Gaelle Guillerm,Bruno Villemagne,B. Audhui,Eric Solary,Francis Witz,Jean Luc Harousseau,Chantal Himberlin,T. Lamy,Bruno Lioure,Marie-Christine Béné,Jean-Yves Cahn,François Dreyfus,Patrick Mayeux,Catherine Lacombe +26 more
TL;DR: This study focused on the PI3K/AKT and mTOR/P70S6K activity in primary blast cells purified from the bone marrow of patients with primary or secondary AMLs, finding that p110 delta was the only consistently expressed isoform and a potential therapeutic value of inhibiting mTOR and P110 delta activity was found.